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Cytolytic and ion channel-forming properties of the N terminus of
lymphocyte perforin
DAVID M. OJCIUS*, PEDRO M. PERSECHINIt, Li MOU ZHENG*, PAULO C. NOTAROBERTOt,
SANDRO C. ADEODATOt, AND JOHN DING-E YOUNG*
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ABSTRACT Perforin lyses cells by binding to the target
cell membrane, where it polymerizes into large nonspecific
pores. It is shown here that the first 34 amino acids of the
N-terminal region of either human or murine perforin are
soluble in aqueous medium and spontaneously insert into
membranes. The N-terminal peptides lyse liposomes and nu-
cleated cells, and they form ion channels in planar bilayers,
some ofwhich are comparable to those previously described for
perforin. The lytic activity of the N-terminal domains does not
require calcium, is independent of the lipid headgroup com-
position, and can be inhibited by heparin. Tumor cells incu-
bated with the N-terminal peptides undergo the same morpho-
logical changes as those induced by native perforin. None of the
peptides corresponding to the putative membrane-spanning
domains from the central region of perforin is cytolytic. Taken
together, these results suggest that the N-terminal region is an
important part of the pore-forming domain of perforin.
Cytotoxic T lymphocytes and natural killer cells endow the
body with an effective barrier against cancerous and virally
infected cells. These effector lymphocytes have been shown
to produce a 70-kDa pore-forming protein, called perforin or
cytolysin, that binds to target cell (TC) membranes, where it
polymerizes into barrel-stave pores with internal diameters of
up to 20 nm (1-5). Purified perforin has potent lytic activity,
and it can lyse a wide variety of targets, including erythro-
cytes, nucleated cells, and artificial lipid vesicles. In lipid
bilayers, perforin forms voltage-insensitive and ion-non-
selective channels that remain preferentially in the open
state. The channels are heterogeneous in size, averaging 400
pS/unit in 0.1 M NaCl (6).
The central one-third of the perforin amino acid sequence
displays extensive homology with the amino acid sequences
of C6, C7, C8, and C9, the terminal components of the
membrane attack complex (MAC) of complement, except at
the C and N terminii, which are specific to perforin (7).
Because of its homology with the putative membrane-
spanning domain of the MAC components, the central region
of perforin was thought to contain the perforin lytic domain.
To identify the perforin lytic domain, synthetic peptides were
therefore made based on the sequence of four regions from
the central region predicted to have amphiphilic structures.
However, unlike monomeric C9, which binds to a preassem-
bled C5b-C6-C7-C8 complex on the TC membrane, mono-
meric perforin binds to membrane lipids in the absence ofany
protein receptor. Thus, the perforin-specific peripheries were
also investigated for a domain that might be directly lytic to
membranes. In this work, a highly lytic domain was in fact
located in the N terminus of perforin.
EXPERIMENTAL PROCEDURES
Cells, Antibodies, Perforin Purification, and Synthesis of
Peptides. The murine cytolytic cell lines CTLL-R8 and
CTLL-2 and the murine tumor cell lines P815, Yac-1, and
EL-4 were maintained as described (8). Perforin was purified
from CTLL-R8 cells as described (8). One hemolytic unit
(HU) is defined as the amount of perforin required to lyse 107
erythrocytes in 140 gl (8).
Peptides were synthesized at the Sloan-Kettering Micro-
chemistry Core Facility on an Applied Biosystems peptide
synthesizer following standard procedures. The peptides
were purified to homogeneity by HPLC, after which they
were lyophilized and analyzed for amino acid content.
Preparation of Lipid Vesicles and Measurement of Carboxy-
fluorescein (CF) Release. Phosphatidylcholine (PC) large unil-
amellar vesicles (LUVs) were made with 50% PC (type IIS;
Sigma) and 50o cholesterol (Calbiochem-Behring) by the
reverse evaporation method (9) in the presence of 100 mM
CF, 50 mM NaCl, and 10 mM Hepes (pH 7.4). External CF
was removed on a Sephadex G-50 column using 150 mM
NaCl and 10 mM Hepes (pH 7.4). CF release from 1-2%
(wt/vol) LUVs was measured in an SLM Aminco (Urbana,
IL) 500C spectrofluorometer at an excitation wavelength of
490 nm and an emission wavelength of525 nm (21-240C). For
calibration, 100%o lysis was determined by diluting a 1%
Triton X-100 solution 50-fold into the cuvette. Phosphatidyl-
serine (PS) LUVs were made as described above, except that
PC was replaced by PS (Avanti Polar Lipids).
Cell Lysis Assays. Perforin- or peptide-mediated lysis of
nucleated cells was detected by the 5"Cr-release assay (8).
Spontaneous release was considered as the 51Cr release from
cells incubated with medium alone or, in the case of compe-
tition assays with liposomes, from cells incubated in medium
with the liposomes but without peptide. The radioactivity
from cells lysed with 1% SDS was used as the total release,
and 51Cr release was calculated as % specific release =
(experimental release - spontaneous release/total release -
spontaneous release) x 100.
The competition assay was used for comparing the ability
of liposomes to absorb peptide from a reaction medium
containing peptide and 51Cr-labeled nucleated cells. Indi-
cated concentrations ofPC or PS LUVs were resuspended in
triplicate in 100 ,ul ofphosphate-buffered saline (PBS, pH 7.4)
containing 14 ,uM human N-terminal peptide (HuNP) and
mixed in microtiter wells with 100 p.1 of 51Cr-labeled cells (5
x 105 cells per ml). Percent specific inhibition was calculated
as (1 - % specific release in experiment/% specific release
in control) x 100. For the control, PBS without liposomes
was mixed with peptide and 51Cr-labeled cells.
Abbreviations: LUV, large unilamellar vesicle; HU, hemolytic
unit(s); CF, carboxyfluorescein; MAC, membrane attack complex;
PS, phosphatidylserine; PC, phosphatidylcholine; TC, target cell;
HuNP, human N-terminal peptide; MuNP, murine N-terminal pep-
tide; CP, C-terminal peptide.
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Perforin-Mediated Hemolysis. Purified perforin in PBS was
added, 1304ul per well, in triplicates to 96-well plates; 10 /ul
of erythrocyte suspension (109 cells per ml) and 10 /4 of 20
mM CaCl2 were then added sequentially. For experiments
where the effects of inhibitors were assayed, 120 /4 of PBS
per well contained the indicated final concentration of hep-
arin or antibodies. Hemolysis was determined spectropho-
tometrically as described (10). The effects of heparin or
antibodies on the membrane binding and insertion activities
of perforin were dissociated following a previously published
protocol (10, 11). Polyclonal antisera (IgG fraction) against
perforin (12) and against a peptide consisting of amino acids
1-19 of the human perforin sequence (13) were already
described. Nonspecific IgG was used as a negative control.
Electron Microscopy. After treatment with murine N-ter-
minal peptide (MuNP) or HuNP, cells were fixed by mixing
with the same volume of 4% glutaraldehyde, 1% paraform-
aldehyde, and 0.1 M phosphate (pH 7.2) at 4TC for 2 hr. After
rinsing, the cell pellets were postfixed with 2% OS04 in the
same buffer for 30 min. The pellets were dehydrated with
ethanol and propylene oxide and embedded in Epon 812. For
comparison, P815 cells were incubated for 1 hr with 33 HU
of perforin per ml.
Planar Bilayers and Current Measurements. Lipid bilayer
membranes were formed by the painting technique (14) using
either a mixture of 30% phosphatidylethanolamine/PC/PS
(10:3:3) in decane or 15% asolecithin (type II; Sigma) in
decane. The experimental chamber was divided into two
2.5-ml compartments as described (15). The cis side con-
tained 150 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, and 10 mM
Hepes (pH 7.4). The trans side was held at virtual ground and
contained 5 mM NaCl, 150 mM KCl, 1 mM MgCl2, 1 mM
EGTA, and 10 mM Hepes (pH 7.4). Peptides were added to
the cis side.
RESULTS
Selection of Peptides. Seven synthetic peptides were made
based on the published sequence of murine and human
perforin (16-19). As a Kyte-Doolittle hydropathic plot pre-
dicts that four perforin regions could form amphiphilic do-
mains (Fig. 1), peptides were made corresponding to murine
amino acids 189-218 (a,), 237-266 (13i), 402-422 (a2), and
104-132 (132). a, would be amphiphilic if in an a-helical
configuration and was initially assumed to be a good candi-
date for membrane spanning/pore-forming domain; compa-
rable amphipathic stretches are present in all of the MAC
components. Although only partially conserved in C8 and C9
and not at all in C7, t3i would be very amphiphilic if in the
,8-sheet configuration and contains at the C end a cluster of
+ ++ + - +
a1 HkHRIUSSY kTHflTVDL GGRISYIT&L
+ --+++ ++
Pi JNVEMQVSIG Q,&SVSSEXK ACEEKKKQHK
+- + + +
P2 INNDHRYPLD YNrR.EEAR &SVAGSHSK
+
02 RAEHLWGDT TATDAYULKVF F
+- + ++
MUNP T=TRSEf KQKHKFVPGV WMAGEgT TJRR
+ +- +++- ++
HuNP £QHTAARSE9 KRSHKEVPGA LAGEGVDVT SLRR
CP YAjQGLLDj PGNRSGAVW
FIG. 1. Amino acid sequences (one-letter code) of the peptides
used in these studies. Hydrophobic residues are underlined, and
charged residues are indicated by a sign above the residue.
melittin-like positive charges (20). Two other potential can-
didates long enough to span the membrane are 2, which is
conserved in C8a, C8.8, and C9, and the nonconserved a2.
Inspection of the perforin sequence suggested one other
likely pore-forming domain, the N-terminal domain, which
contains an amphiphilic stretch long enough to span the
membrane. Peptides were thus made for the human (HuNP,
amino acids 1-34) and murine (MuNP, amino acids 1-34)
N-terminal regions (Fig. 1). Finally, as a negative control, a
seventh peptide was made corresponding to the murine
C-terminal region (CP, amino acids 516-534) (Fig. 1).
N-Terminal Peptide Lyses Lipid Vesides. LUVs made with
PC by the reverse evaporation method (9) were prepared in
the presence of 100 mM CF, a concentration at which this
fluorescent dye is self-quenching, and external dye was
removed by chromatography. Lysis of LUVs leads to a
dilution of CF and thus an increase in fluorescence. The
C-terminal peptide, CP, had no effect on CF release from
LUVs. In contrast, significant CF release was produced by
'10 pg/ml (%3 pAM) of either HuNP or MuNP (data shown
forMuNP in Fig. 2a), which are easily soluble in PBS at room
temperature. Although native perforin requires calcium and
37TC for its lytic activity to be expressed, HuNP and MuNP
are lytic in the total absence of divalent cations.
Heparin and serum lipoproteins inhibit perforin-mediated
lysis, and it has been proposed that the role ofthese inhibitors
is to prevent lysis of innocent bystander cells outside of the
contact zone formed between cytotoxic T lymphocytes and
TCs (11, 21). Perforin-mediated lysis is blocked by the serum
proteins only if the inhibitors are added before perforin but
not if perforin has already bound to the TCs (11). Lysis of
LUVs by HuNP or MuNP can be completely inhibited by
heparin at 25 pug/ml. Unlike the case for perforin (10, 11),
though, lysis by the N-terminal peptides can be blocked even
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FIG. 2. (a) Lysis of CF-containing liposomes due to increasing
concentrations (shown above each lysis curve) ofMuNP. MuNP was
added where denoted by the arrow. (b) Inhibition ofHuNP-mediated
lysis by heparin. Heparin was added to the cuvette at a final
concentration of 25 ,ug/ml at the time denoted by the second arrow.
The dotted line shows the continuation of lysis in the absence of
heparin.
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2b). Heparin has no effect on lysis of liposomes due to the
lytic bee venom toxin melittin at 10 Ag/ml (data not shown).
As a first step toward defining the minimum length for lytic
activity of the N-terminal domain, a peptide was made
corresponding to the first 19 amino acids of HuNP. The lytic
activity of this peptide was comparable to that ofHuNP (data
not shown), implying that the remainder of the sequence of
HuNP or MuNP may not be required for lysis of LUVs.
The peptides corresponding to the perforin regions dis-
playing homologies with the MAC components were also
investigated. a1, f1, a2, and P2 were dissolved at 5 mg/ml in
an 8 M urea buffer, and their ability to lyse LUVs was tested;
the urea control (80 mM urea) was not lytic. Neither a2 nor
/32 (50 Ag/ml) had any noticeable effect on CF release from
LUVs. On the other hand, relatively high concentrations
(250 Ag/ml) of a1 or Pf gave rise to small but reproducible CF
release from LUVs, suggesting that, though only slightly lytic
to liposomes and inoffensive to nucleated cells (see below),
these perforin domains may participate with the N-terminal
domain in subsequent perforin insertion and polymerization.
N-Terminal Peptide Lyses Tumor Cells and Cytolytic Lym-
phocytes. Perforin can lyse liposomes and nucleated cells, but
cytolytic lymphocytes are remarkably refractory to perforin-
mediated lysis (22), consistent with the observation that
cytotoxic T lymphocytes and natural killer cells lyse their
targets without incurring self-damage. As shown in Fig. 3a,
perforin effectively lyses the mastocytoma cell line P815,
whereas the CTL cell line CTLL-R8 is extremely resistant to
lysis. Similar results were obtained with the perforin-
susceptible cell lines EL-4 and Yac-1 and the perforin-
resistant CTL cell line CTLL-2 (data not shown). To deter-
mine whether nucleated cells can be lysed by the N-terminal
peptides, P815 cells and CTLL-R8 cells were preloaded with
Na251CrO4 and then incubated with MuNP or HuNP. The
perforin-susceptible P815 and the perforin-resistant CTLL-
R8 cell lines were effectively lysed by the N-terminal pep-
tides, as determined by their ability to release 51Cr-labeled
proteins from the cells (data shown for HuNP in Fig. 3b). On
the other hand, a1, 831, and the C-terminal domain, CP, were
innocuous to P815 and CTLL-R8 cells (data shown for CP in
Fig. 3b). Similar results were obtained with Yac-1 and EL-4
cells (data not shown).
It is still not clear whether there is a strict lipid headgroup
requirement for perforin-mediated lysis. Although it had been
proposed that PC behaves as a calcium-dependent receptor
for perforin (23), measurements in which liposomes were
directly lysed by perforin-containing granules showed that
perforin can lyse membranes regardless of their lipid com-
position (24), and inhibition of perforin-mediated lysis by
lysolipids is independent ofthe lysolipid headgroup (10). P815
cells were loaded with Na251CrO4 and the ability of PC or PS
LUVs to inhibit HuNP-mediated lysis of P815 cells was
measured. The principle behind this competition assay is that
LUVs to which HuNP is capable ofbinding should inhibit cell
lysis better than those LUVs to which HuNP cannot bind (8).
As seen in Fig. 3c, PC and PS LUV are equally effective at
blocking lysis of P815 by HuNP, implying that HuNP can
bind equally well to PC or PS.
Antibody Against an N-Terminal Peptide Blocks Perforin
Binding to Membranes. As an antibody against the perforin N
terminus inhibits perforin-mediated hemolysis (Table 1), it
became of interest to try to dissociate between the effects of
the antibody on perforin membrane binding and on the
membrane insertion or lytic activity of perforin. These ex-
periments take advantage ofthe observation that perforin can
bind to membranes at 0°C and that hemolysis does not take
place unless the temperature is increased (11). Heparin
inhibits hemolysis if it is added to erythrocytes before per-
forin binds to the membranes but not if perforin is already
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FIG. 3. (a) Perforin-mediated lysis of P815 cells and CTLL-R8
cells. Percent specific cytotoxicity was measured by the 51Cr-release
assay. (b) HuNP-mediated lysis of P815 cells and CTLL-R8 cells.
The lack of effect of CP on P815 cells is shown on the same graph.
(c) Inhibition of HuNP-mediated cytolysis by lipid. The indicated
concentrations of PC or PS LUVs and 14 MAM HuNP in 100 ,ul were
mixed with 100 MAl of 51Cr-labeled P815 cells.
peptide and against native perforin inhibit hemolysis only at
the membrane-binding stage (Table 1).
Cell Death Induced by the N-Terminal Peptides Is Morpho-
logically Similar to That Produced by Perforin. Cell lysis due
to either the N-terminal peptides or perforin was observed by
transmission electron microscopy. Initially, assault of P815
cells (Fig. 4a) with MuNP leads to extensive "boiling" of the
cytoplasm, disruption of the mitochondrial structure, and
Table 1. Effect of antibodies and heparin on the binding and
pore-insertion stages of perforin-mediated hemolysis
% hemolysis
Addition Membrane binding Pore insertion
None (control) 99 99
Heparin 7 93
Anti-N-terminal peptide 4 83
Anti-perforin 5 65
The membrane binding and pore-insertion or polymerization
stages ofperforin-mediated hemolysis were measured as described in
the text. Antibodies against an N-terminal peptide or against native
perforin were used at a final concentration of 6 ,g/ml. Heparin was
used at a final concentration of 25 ug/ml.
Immunology: Ojcius et al.
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FIG. 4. Lysis of P815 cells due to treatment with 14NM MuNP for 0 (a), 5 (b), and 30 min (c) at room temperature. (Bar = 1.2 Am.)
flocculation of the nuclear chromatin (Fig. 4b). The chroma-
tin eventually disappears, and the cells swell and many are
observed to burst (Fig. 4c). A similar series of morphological
changes, typical of necrosis but distinct from apoptosis (25),
was observed when cells were incubated with HuNP or
purified perforin (data not shown; ref. 26).
The N-Terminal Peptides Form Single Channels in Planar
Lipid Bilayers. HuNP and MuNP were next tested on a lipid
bilayer system. Addition of either peptide to the cis side at a
final concentration of 10-20 jig/ml causes a conductance
increase that leads to membrane disruption, as gauged by a
sharp current increase and saturation of the amplifier output
(Fig. 5a). At smaller concentrations, gradual step-like con-
ductance increases ranging4rom 200 to 1500 pS and display-
ing stable intermediate stages could also be observed (Fig. 5
b and c). At lower peptide concentrations, HuNP (Fig. Sd)
and MuNP (Fig. 5e) were able to generate transitory con-








channel activity is best observed at potentials not exceeding
±20mV and spontaneous activity can also be observed close
to 0 mV. Current-voltage plots of the largest currents mea-
sured at membrane potentials from -30 to +10 mV displayed
a linear relationship with a slope of 914 pS and a reversal
potential of -2.5 mV (Fig. 5f), suggesting that single channel
conductances are independent of voltage and display poor
selectivity of Na' over K+. In Fig. 5e, the stabler states
observed at +30 and +50 mV (two upper traces) had ampli-
tudes that did not correspond to what would be expected
from a linear current-voltage behavior. Although a strong
rectification may account for the apparent nonlinearity, we
favor the hypothesis that at higher potentials only smaller
channels or substates are detected. The presence of single
events lasting <200 ms that could fall on the straight line
(open circle in Fig. 5J) supports this view, but more exper-
iments are needed to clarify this point. A peptide consisting
of the first 19 amino acids of the human N terminus was also
observed to form stable and step-like pores (data not shown).
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FIG. 5. Conductance increases and ion channel activity induced by HuNP and MuNP in lipid bilayers. (a) Fast membrane disruption with
step-like intermediate states induced by 10 jig ofHuNP per ml. Membrane potential = +60 mV. (b) Slow and step-like transitions in membrane
conductance induced by 1 Ag of HuNP per ml at +10 mV. Notice that the current scale was reduced 10-fold on the right side of the record.
(c) Long-lasting conductance steps obtained with 0.2 jig of MuNP per ml with the membrane potential clamped at +20 mV. (d) Ion channel
activity due to 1 jig ofHuNP per ml at + 10 mV. (e) Channel activity due to MuNP obtained from a single membrane at several holding potentials,
as indicated at the right side of each record. (f) Current (I) vs. voltage (V) plot of the data in e. Largest conductance states were taken from
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DISCUSSION
The lipid bilayer results (Fig. 5) showed that HuNP and
MuNP can form large ion channels with conductances com-
parable to those already described for perforin (6). Other
characteristics ofHuNP and MuNP, such as the formation of
channels displaying multiple sizes, the induction of succes-
sive and long-lasting high conductance states in a stair-like
pattern, and the abrupt conductance increase at higher doses,
also resemble those of perforin. These data, together with the
fact that HuNP and MuNP are lytic to various cell types and
can induce liposome damage, strongly suggest that the N-ter-
minal region is an important part of the pore-forming domain
of perforin. The existence of several channel sizes and/or
substates observed in several records is consistent with the
idea that the N-terminal peptides, like perforin, form high-
conductance channels or pores by polymerization. Addition
of one or more peptides to aggregates of different sizes could
lead to various conductance changes.
As opposed to perforin, which requires Ca2l for its lytic
activity to be expressed (1-4), MuNP and HuNP are lytic in
the absence of any divalent cations. It is possible that the
N-terminal domain may be buried within the perforin protein,
in which case Ca2l would be required to induce a confor-
mational change in perforin that might uncover the lytic
domain. Once the lytic domain is exposed and bound to the
TC membrane, it could facilitate the insertion of the rest of
the perforin molecule into the membrane, at which stage
several membrane-spanning domains could participate simul-
taneously during perforin polymerization into the 20-nm
pores. Heparin and other blood serum proteins would pre-
vent lysis of innocent bystander cells by binding to the
N-terminal domain only if perforin has not yet bound to the
TC membrane; the lytic domain, presumably inserted be-
tween the membrane and the bulk of the protein, would be
inaccessible to the serum proteins once perforin has bound to
the membrane. Consistent with this model, antibodies against
the N-terminal domain are able to intercept perforin-
mediated lysis only if perforin has not yet bound to the
membrane. On the other hand, whatever mechanism protects
cytolytic lymphocytes against self-lysis would have to rec-
ognize some perforin region other than the N-terminal do-
main.
In preliminary experiments, most of the lytic activity of the
N-terminal domain has been located in the first 19 amino
acids. Although many small peptides are known to form
barrel-stave channels, probably the best characterized is a
family of toxins related to alamethicin and produced by the
fungus Trichoderma viride (27). Alamethicin itself has 20
amino acids, and the other members of the family are
between 15 and 24 amino acids long.
Spectroscopic studies have been undertaken to determine
the secondary structure of the perforin N-terminal domain.
Unlike alamethicin, the perforinN terminus does not contain
an amphipathic a-helical stretch long enough to span the
membrane. An alternative mode of pore formation is sug-
gested if the N terminus is divided into three domains,
consisting of amino acids 1-5 (domain A), 6-16 (domain B),
and 17-19 (domain C). Domain A is mildly hydrophobic and
domain C is strongly hydrophobic, whereas domain B is
predominantly hydrophilic. However, the hydrophobic and
charged residues in the murine domain B are distributed in
such a way that an amphipathic /B-strand could be formed.
The human domain B has almost the same structure, except
that an arginine at position 12 disrupts the amphipathic
character. However, as previously pointed out (28), interac-
tions between proteins and membranes are less specific than
those between proteins and proteins, so that substitution of
a single residue in a particular location by one of an appar-
ently opposite hydrophobicity does not represent an intoler-
able deviation from the peptide's amphipathicity. An attrac-
tive feature of the amphipathic /-sheet model for domain B
is that amphipathic /3-sheets have a tendency to self-associate
(29) and can traverse the membrane as long as they contain
at least 10 amino acids. If it turns out that experimental
studies confirm this model, then the perforn N terminus
would join the growing category of transmembrane peptides
and proteins that lack hydrophobic sequences long enough to
span the membrane. The best known examples are porins,
which create pores across the outer membrane ofEscherichia
coli. The bulk of this largely hydrophilic protein exists within
the lipid bilayer, and its secondary structure appears to
consist mostly of antiparallel /3-pleated sheets (30).
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